Floatz logo

E-6201

Metastatic Malignant Neoplasm in the Central Nervous System

Mayo ClinicSmall moleculePhase 1Active
D
27/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
12/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Metastatic Malignant Neoplasm in the Central Nervous System cohort.

Asset / SponsorPhaseRating
Brigatinib
Sameek Roychowdhury
Phase 2CCC
CBL-0137 FREE BASE
Children's Oncology Group
Phase 1/2CC
wsd0922-fu
Mayo Clinic
Phase 1CC
Dabrafenib
Mayo Clinic
Phase 1CC

Same molecule, other indications

E-6201 is also rated in:

acute myeloid leukemiaDormant
D
Indicative ·
30 / 100
View asset →
myelodysplastic syndromeDormant
D
Indicative ·
30 / 100
View asset →
chronic myelomonocytic leukemiaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →